Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APEN NYSE:BVS NYSE:CATX NYSE:INFU On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPENApollo Endosurgery$9.94$3.49▼$10.30$579.72M2.311.43 million shs1.66 million shsBVSBioventus$7.27+0.8%$6.96$5.81▼$14.38$601.08M0.84398,468 shs235,027 shsCATXPerspective Therapeutics$3.37-1.7%$3.75$1.60▼$16.31$250.27M1.2920,524 shs326,663 shsINFUInfuSystem$10.42+1.6%$7.79$4.61▼$11.04$209.57M1.82179,389 shs316,773 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPENApollo Endosurgery0.00%0.00%0.00%0.00%0.00%BVSBioventus+0.83%+0.69%+5.06%+8.35%-30.76%CATXPerspective Therapeutics-1.75%+1.51%-8.42%+2.74%-78.41%INFUInfuSystem+1.56%-1.51%+18.01%+71.10%+72.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPENApollo Endosurgery$9.94$3.49▼$10.30$579.72M2.311.43 million shs1.66 million shsBVSBioventus$7.27+0.8%$6.96$5.81▼$14.38$601.08M0.84398,468 shs235,027 shsCATXPerspective Therapeutics$3.37-1.7%$3.75$1.60▼$16.31$250.27M1.2920,524 shs326,663 shsINFUInfuSystem$10.42+1.6%$7.79$4.61▼$11.04$209.57M1.82179,389 shs316,773 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPENApollo Endosurgery0.00%0.00%0.00%0.00%0.00%BVSBioventus+0.83%+0.69%+5.06%+8.35%-30.76%CATXPerspective Therapeutics-1.75%+1.51%-8.42%+2.74%-78.41%INFUInfuSystem+1.56%-1.51%+18.01%+71.10%+72.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPENApollo Endosurgery 0.00N/AN/AN/ABVSBioventus 2.75Moderate Buy$13.7589.13% UpsideCATXPerspective Therapeutics 3.18Buy$12.56272.57% UpsideINFUInfuSystem 4.00Strong Buy$12.5019.96% UpsideCurrent Analyst Ratings BreakdownLatest APEN, BVS, CATX, and INFU Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$12.007/21/2025INFUInfuSystemRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/12/2025CATXPerspective TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.006/23/2025CATXPerspective TherapeuticsB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$9.00 ➝ $12.006/23/2025CATXPerspective TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$11.00(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPENApollo Endosurgery$76.86M0.00N/AN/A$0.69 per share0.00BVSBioventus$564.14M1.07$0.58 per share12.58$2.80 per share2.60CATXPerspective TherapeuticsN/AN/AN/AN/A$2.67 per shareN/AINFUInfuSystem$139.89M1.52$0.81 per share12.79$2.47 per share4.22Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPENApollo Endosurgery-$39.84M-$1.02N/AN/AN/A-51.84%-89.48%-33.76%N/ABVSBioventus-$156.23MN/AN/A15.80N/A-7.11%15.61%4.01%N/ACATXPerspective Therapeutics-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%11/11/2025 (Estimated)INFUInfuSystem$870K$0.23173.7033.61N/A1.12%2.78%1.41%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPENApollo EndosurgeryN/AN/AN/AN/AN/ABVSBioventusN/AN/AN/AN/AN/ACATXPerspective TherapeuticsN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPENApollo Endosurgery1.042.351.89BVSBioventus1.851.410.99CATXPerspective TherapeuticsN/A9.609.60INFUInfuSystem0.501.981.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPENApollo Endosurgery76.01%BVSBioventus62.94%CATXPerspective Therapeutics54.66%INFUInfuSystem71.13%Insider OwnershipCompanyInsider OwnershipAPENApollo Endosurgery17.30%BVSBioventus33.00%CATXPerspective Therapeutics3.52%INFUInfuSystem10.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPENApollo Endosurgery20257.97 million47.94 millionNot OptionableBVSBioventus1,20082.68 million54.46 millionNot OptionableCATXPerspective Therapeutics7074.26 million65.21 millionOptionableINFUInfuSystem41020.43 million19.10 millionOptionableAPEN, BVS, CATX, and INFU HeadlinesRecent News About These CompaniesPunch & Associates Investment Management Inc. Sells 345,000 Shares of InfuSystem Holdings, Inc. $INFUSeptember 9 at 5:31 AM | marketbeat.comHsbc Holdings PLC Purchases Shares of 27,026 InfuSystem Holdings, Inc. $INFUSeptember 8 at 3:13 AM | marketbeat.comAmerican Century Companies Inc. Invests $256,000 in InfuSystem Holdings, Inc. $INFUSeptember 8 at 3:12 AM | marketbeat.comNuveen LLC Invests $465,000 in InfuSystem Holdings, Inc. $INFUSeptember 7 at 3:14 AM | marketbeat.comAWM Investment Company Inc. Has $8.75 Million Stake in InfuSystem Holdings, Inc. $INFUSeptember 5, 2025 | marketbeat.comInfuSystems Holdings, Inc. (INFU) Is Up 12.64% in One Week: What You Should KnowSeptember 2, 2025 | zacks.com5 Stocks With Recent Price Strength to Tap Wall Street RallySeptember 2, 2025 | zacks.comInfuSystems Holdings (INFU) is on the Move, Here's Why the Trend Could be SustainableAugust 29, 2025 | zacks.comRussell Investments Group Ltd. Grows Stake in InfuSystem Holdings, Inc. $INFUAugust 28, 2025 | marketbeat.comInfuSystems Holdings, Inc. (INFU)'s Technical Outlook is Bright After Key Golden CrossAugust 27, 2025 | zacks.comInfuSystem: A New Sheriff In TownAugust 26, 2025 | seekingalpha.comHow Much Upside is Left in InfuSystems Holdings (INFU)? Wall Street Analysts Think 41.07%August 25, 2025 | zacks.comInfuSystem (NYSE:INFU) Director Sells $55,621.84 in StockAugust 23, 2025 | insidertrades.comGrab These 4 Stocks With Solid Net Profit Margins to Boost ReturnsAugust 21, 2025 | zacks.com4 Medical Product Stocks to Watch From a Challenging IndustryAugust 14, 2025 | zacks.comAre You Looking for a Top Momentum Pick? Why InfuSystems Holdings, Inc. (INFU) is a Great ChoiceAugust 13, 2025 | zacks.comRecent Price Trend in InfuSystems Holdings (INFU) is Your Friend, Here's WhyAugust 13, 2025 | zacks.comWhy InfuSystems Holdings (INFU) Might be Well Poised for a SurgeAugust 8, 2025 | zacks.comCan InfuSystems Holdings (INFU) Climb 79.52% to Reach the Level Wall Street Analysts Expect?August 8, 2025 | zacks.comAre Investors Undervaluing InfuSystems Holdings (INFU) Right Now?August 8, 2025 | zacks.comNew Strong Buy Stocks for August 8thAugust 8, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAPEN, BVS, CATX, and INFU Company DescriptionsApollo Endosurgery NASDAQ:APENApollo Endosurgery, Inc. is a medical technology company, which focuses on the design, development, and commercialization of medical devices to advance gastrointestinal therapeutic endoscopy. It offers Endoscopy, Surgical and Other products. The firm's endoscopy product portfolio consists of the OverStitch Endoscopic Suturing System, the OverStitch Sx Endoscopic Suturing System, and the Orbera Intragastric Balloon System. Its products are used by gastroenterologists and bariatric surgeons in a variety of settings to treat multiple gastrointestinal conditions including closure of acute perforations and chronic fistulas, inadvertent perforation of the GI tract, tissue closure after the removal of abnormal lesions in the esophagus, stomach or colon, the treatment of swallowing disorders, esophageal stent fixation, and obesity. The company was founded by Christopher J. Gostout and Dennis L. McWilliams in 2005 and is headquartered in Austin, TX.Bioventus NYSE:BVS$7.27 +0.06 (+0.83%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$7.27 0.00 (0.00%) As of 09/9/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Perspective Therapeutics NYSE:CATX$3.37 -0.06 (-1.75%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$3.37 0.00 (0.00%) As of 09/9/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.InfuSystem NYSE:INFU$10.42 +0.16 (+1.56%) Closing price 09/9/2025 04:00 PM EasternExtended Trading$10.41 -0.01 (-0.06%) As of 09/9/2025 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Qualcomm Tesla’s Next Rival in Autonomous Driving? Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
